APPENDIX F: To be used, when Recipient Institution of Master Agreement (herein Appendix F referred to as “Provider”) transfers Derived Material to IU at the NCRAD facility.

APPENDIX F

MATERIAL TRANSFER AGREEMENT
FOR THE TRANSFER OF DERIVED MATERIALS TO NCRAD

This Material Transfer Agreement for the Transfer of Derived Materials to NCRAD (“Agreement”) is made and entered into by and between The Trustees of Indiana University having offices at 980 Indiana Avenue, LV2232, Indianapolis, IN 46202, USA (hereinafter “IU”) and the Providing Institution identified on the signature page below (“Provider”) jointly referred to as the parties. This Agreement is effective as of date of the last signature below ("Appendix F Effective Date") and results from the terms and conditions of the “Master Material Transfer Agreement for the Transfer of Materials from NCRAD” between the parties with an Effective Date of ________________ (hereinafter “Master Agreement”).

Whereas IU operates the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), a biorepository located within Indiana University, and which was originally established through funding from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), an agency of the Public Health Service (PHS) and the U.S. Department of Health & Human Services (HHS), to help address the public health needs for continued research concerning Alzheimer’s Disease and related neurological diseases and aging; and

Whereas IU provided Original Research Material to Provider;

Whereas Provider generated Derived Materials (as defined in Master Agreement) under the terms and conditions of the Master Agreement;

Whereas Provider agreed in the Master Agreement to transfer Derived Materials (defined in Master Agreement) to IU at their NCRAD facility for distribution by NCRAD to nonprofit and for-profit organizations for furthering non-commercial research concerning Alzheimer’s Disease and related neurological diseases and aging;

Whereas Provider has obtained and generated Derived Material in compliance with all applicable statutes, rules, and regulations; and

Whereas Provider desires NCRAD, after consultation with the NIA and the relevant NCRAD advisory committee, to distribute Derived Material to qualified investigators in the research community.

Now Therefore, Provider and IU enter into this Agreement governing the transfer and use of Derived Material.

1. The parties to this Appendix F (“Agreement”) are parties to the Master Agreement identified above and desire to execute this Agreement as a result of the terms and conditions of the Master Agreement. Except as defined in this Agreement, all other capitalized terms shall be as defined in the Master Agreement.

2. The terms and conditions of this Agreement shall be consistent with the Master Agreement.

3. Provider agrees, at its own expense, to transfer to IU (at the NCRAD facility) at least two vials of the Derived Material(s) listed below as well as documentation adequate to enable NCRAD
investigators to culture and/or maintain Derived Material. At any time, with the consent of IU, Provider may transfer additional vials of the same listed Derived Materials to IU under this Agreement.

List Derived Materials: (Attach additional sheet if needed).

4. DERIVED MATERIAL MAY NOT BE USED IN EXPERIMENTS INVOLVING HUMAN SUBJECTS. IU agrees to comply with all Federal rules and regulations applicable to the use and handling of the Derived Material.

5. Derived Material will be used by NCRAD solely for teaching, noncommercial research purposes, and for subsequent distribution restricted to not be for Commercial Use. NCRAD will prepare and maintain Derived Material as appropriate in its facility, and will ship Derived Material to third party requesters under the terms and conditions of MASTER MATERIAL TRANSFER AGREEMENT FOR THE TRANSFER OF MATERIALS FROM NCRAD.

6. Derived Material transferred from Provider to IU pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED INCLUDING, BUT NOT LIMITED TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE DERIVED MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. Unless prohibited by law, IU assumes liability only for claims for damages which may arise from the use, storage, or disposal of the Derived Material by IU to the extent permitted by law. All cultured animal and human tissue cells have the potential for carrying viruses, latent viral genomes, and other infectious agents in a non-apparent state. Accordingly, IU shall adhere to the applicable guidelines for appropriate laboratory procedure.

7. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, and all of such counterparts shall together constitute one and the same agreement.

[Signatures on following page]
IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date by their authorized representatives.

Agreed:

Name of Provider:

By: ___________________________   _________
Authorized Official of Provider                     Date
Name: __________________________    
Title: ________________________________________

The Trustees of Indiana University

By: ___________________________   _________
Authorized Official                     Date
Name: __________________________    
Title: ________________________________________

Signature of NCRAD Investigator                     Date
Name: __________________________    
Title: ________________________________________

LEGAL ADDRESS:
Office of Research Administration
Indiana Avenue, LV2232
Indianapolis, IN 46202
Email: mtas@iu.edu

NCRAD ADDRESS:
Division of Hereditary Genomics
Indiana University
410 West 10th Street, HS 4000
Indianapolis, IN 46202-3002